Script Notes. Treatment of Mild to Moderate Asthma. In This Issue: Script Notes Has a New Look!
|
|
- Adela Mills
- 5 years ago
- Views:
Transcription
1 Script Notes Third Quarter 2006 The Pharmacy and Therapeutics Newsletter for Keystone Mercy Health Plan Participating Providers In This Issue: Treatment of Mild to Moderate Asthma Formulary Update Product Update Zocor, Zoloft, and Proscar Available as Generic Products.. 3 Safety Alerts References Script Notes Has a New Look! We have made some changes to our format to help make Script Notes easier to read. Please let us know what you think by ing : andrew.maiorini@performrx.com. Treatment of Mild to Moderate Asthma Statistics from the American Lung Association showed that, by far, most people with asthma (88% or 16.6 million people in the United States) have a diagnosis of mild to moderate asthma. Many of these patients can be controlled on inhaled cortico-steroids, which is the standard of treatment. A 2005 Public Health advisory published by the FDA stated that products containing Long Acting Beta Agonists (LABAs) should not be used as a first line treatment for asthma. LABAs should be added to a treatment plan only if other medicines, including low-or-medium-dose inhaled corticosteroids, do not control asthma. Corticosteroid agents on Keystone Mercy Formulary include: Qvar (beclomethasone), Asmanex (mometasone), Azmacort (triamcinolone) and Flovent (fluticasone). A large placebo-controlled U.S. study, the Salmeterol Multi-Center Asthma Research Trial (SMART), compared the safety of salmeterol or placebo added to usual asthma therapy. The data showed an increase in asthma-related deaths in patients receiving salmeterol: 13 deaths out of 13,176 patients treated for 28 weeks on salmeterol 3 deaths out of 13,179 on placebo Advair (fluticasone/salmeterol xinafoate) is not indicated in patients whose asthma can be successfully managed by inhaled corticosteroids along with occasional use of inhaled short-acting beta2-agonists. In July 2006, a new agent Symbicort (budesonide and formoterol) was approved. It contains a corticosteroid and long-acting beta2-agonist. 88% or 16.6 million people in the United States have a diagnosis of mild to moderate asthma. According to a study, The Treatment of Asthma Study XXII, inhaled corticosteroids are prescribed in fewer than one out of three patients as initial therapy for mild-persistent asthma. A step-therapy approach should be used when initiating therapy with a newly diagnosed member based on his or her symptoms and the severity and frequency of the symptoms. As a provider, you can influence the health outcomes of our members. Please review their asthma therapy, calculate compliance, and, from time to time, review inhaler technique with members. These steps can assure appropriate therapy and increase positive outcomes. For more information about Script Notes, or questions about our formulary please visit our website: 1
2 Formulary Update: Additions to the Keystone Mercy Drug Formulary Drug Additions to Formulary Effective Date Alphagan P June 2006 Diovan HCT 320/12.5 June 2006 Diovan HCT 320/25 June 2006 Asmanex Twisthaler June 2006 Alphagan P 0.1% (brimonidine tartrate) Indication: For lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. Made by Allergan, Inc., Alphagan P, 0.1% ophthalmic solution (brimonidine tartrate) was approved by the FDA in August The approval was based on study data showing that the 0.1% and 0.2% (Alphagan) formulations were similarly effective for reducing IOP. The product s increased bioavailability allows a further decrease in drug exposure compared with the previously approved and equally effective 0.15% formulation. All product formulations of Alphagan P are formulary agents for Keystone Mercy Health Plan members. Diovan HCT 320/12.5 and Diovan HCT 320/25 Indication: These two new higher-dose formulations of Diovan HCT are now available for patients with hypertension. Diovan HCT contains the angiotensin receptor blocker valsartan and the diuretic hydrochlorothiazide (HCTZ). Many patients need a combination of two therapies to achieve blood pressure goals. The higher doses provided significantly greater reductions in blood pressure compared with either agent alone. Giving this combination also reduced the incidence of low blood potassium, which is associated with HCTZ. Dosing: The tablets are already available in combinations of 80/12.5, 160/12.5, and 160/25 mg. Asmanex Twisthaler (mometasone) Indication: For the maintenance of asthma as prophylactic therapy in patients 12 years of age and older. Asmanex is also indicated for asthma patients that require oral corticosteroid therapy, where adding Asmanex may reduce or eliminate the need for oral corticosteroids. Asmanex is administered by inhalation route. Mometasone is a corticosteroid that demonstrates potent anti-inflammatory activity. The systemic availability of mometasone when inhaled has been determined to be less than 1%. Currently inhaled corticosteroids are a first line treatment in patients with persistent mild to moderate asthma. The inhalation device provides a dose of 220 mcg per actuation. Dosing: The recommended dosing frequency is once or twice daily. Once daily dosing is unique to this product when compared to other dry powder corticosteroid inhalers. It is recommended that when dosing once daily, Asmanex should be taken in the evening. The starting dose depends on the patient s previous therapy and degree of asthma severity. Recommended Dosages Starting Maximum Previous Therapy Dose Daily Dose Bronchodilators only 220 mcg 440 mcg once daily Inhaled corticosteroids 220 mcg 440 mcg once daily Oral corticosteroids 440 mcg 880 mcg twice daily The efficacy and safety of Asmanex at various dosing regimens has been demonstrated in multiple clinical trials involving 1,941 patients with asthma aged 12 years and older. Asmanex is contraindicated in the primary treatment of status asthmaticus or other acute episodes of asthma where intensive measures are required. Asmanex Twisthaler is a device for inhalation of dry powder mometasone. Each actuation delivers 220 mcg. There are four different sizes each providing a different number of total actuations: 14, 30, 60, and
3 Formulary Update: Removed From Formulary: Generic Equivalent of Percodan (Oxycodone and Aspirin) The generic equivalent of Percodan (Oxycodone and Aspirin 325/4.5 mg) has been removed from the formulary. The generic equivalent of Percocet (Oxycodone and Acetaminophen 5/325mg) is offered as a therapeutic alternative. If you feel that generic Percocet is not an appropriate alternative for a patient, you will need to submit a Prior Authorization Request for generic Percodan. Product Updates Please be aware the information discussed in this section is to provide the reader with product updates only. It is not indicative of what is currently or will be on Keystone Mercy s formulary. There have been a few new product releases for the treatment of asthma within the last year. Asmanex Twisthaler inhaled corticosteroid Indicated for asthmatic patients who are 12 years or older Dosed once daily in the evening Available in three different 220 mcg unit dose inhalers: 30 inhalation units, 60 inhalation units, and 120 inhalation units Common adverse events are headache, allergic rhinitis, pharyngitis, and upper respiratory infections Orapred ODT oral disintergrating prednisolone tablet Used to treat exacerbations of asthma in pediatric patients Doses based on weight of the pediatric patient in single or divided doses Tablets available in 10 mg, 15 mg, and 30 mg of the prednisolone base Adverse reactions in clinical trials included: facial edema, pharyngolaryngeal pain, blood in stool, eye irritation, and eyelid edema Tablets should not be cut, split or broken Advair HFA combination product of fluticasone and salmeterol Can be administered twice daily in patients who are 12 years of age or older Available in the following combination doses of Fluticasone and Salmeterol: 45/21mcg, 115/21mcg, and 230/21mcg Common side effects are headaches, upper respiratory tract infections, throat irritation, and dizziness Carries the black box warning in regards to an increase in asthma-related deaths Requires a MedGuide for outpatient use Zocor, Zoloft, and Proscar Available as Generic Products This year several widely used blockbuster medications now have generic alternatives available on the market. Whenever possible, Keystone Mercy strives to increase generic utilization to reduce the cost of medication management for the plan and our members. Simvastatin (generic for brand Zocor ) became available in many pharmacies in June of Simvastatin is the second most frequently prescribed statin on the market today. Statin medications are most often prescribed for patients with hyperlipidemia, a common risk factor for cardiovascular disease. The generic manufacturers Ranbaxy Laboratories (80 mg strength only) and Teva (all other strengths) have exclusivity to market the generic for a period of 180 days. Typically this exclusivity limits the degree to which the price decreases during the initial 180 days. Dr. Reddy s Laboratories, under license from Merck & Co., is also going to be marketing simvastatin during this time period. Simvastatin is currently non-formulary and requires prior authorization (PA) for Keystone Mercy Health Plan. Formulary alternatives to simvastatin, which do not require PA, include lovastatin, Lescol, Lescol XR, Altoprev, and pravastatin (generic Pravachol ). Sertraline (generic for brand Zoloft ) became available in August of Zoloft is a very popular medication belonging to the Selective Serotonin Reuptake Inhibitor (SSRI) class of antidepressants. SSRIs are used to treat depression, anxiety, Post Traumatic Stress Disorder (PTSD), as well as other behavioral health related conditions. Generic manufacturers Roxane Labs (concentrated oral solution only) and Teva will be marketing a generic formulation of sertraline. Also Greenstone LTD, a subsidiary of brand Zoloft patent holder Pfizer Inc., will also be marketing a generic version. Sertraline is currently nonformulary for Keystone Mercy Health Plan. Formulary (continued on page 5) 3
4 Safety Alerts: Warnings Due to outcome of Salmetrol Muliticenter Asthma Research Trial (SMART) May increase the risk of asthma-related deaths Recommend prescribing LABAs only when patients are not adequately controlled on other asthma-controlled medications... or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies. Long-Acting Beta2 Agonist (LABA) Inhalers Advair Diskus (salmetrol and fluticasone combination) and Servent Inhaler (salmeterol) Two of the long-acting beta2 agonist (LABA) inhalers, Advair Diskus (salmetrol and fluticasone combination) and Servent Inhaler (salmeterol), have a black box warning in place due to the outcomes of the Salmetrol Muliticenter Asthma Research Trial (SMART). This black box warning states LABAs may increase the risk of asthma-related deaths. The warning also states physicians should only prescribe LABAs when patients are not adequately controlled on other asthmacontrolled medications (e.g. low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with 2 maintenance therapies. Recently, Foradil Aerolizer (formoterol) had this black box warning put into place as well, due to a recommendation from the FDA Pulmonary and Allergy Drug Advisory panel. Another newly marketed product, Advair HFA, has also included this black box warning. Misadministration Warning Both Sprivia HandiHaler (tiotropium bromide) and Foradil Aerolizer (formoterol) have had reported cases of patients orally ingesting the inhalation capsules. Although these reported cases have had few adverse events, the misadministration does decrease the therapeutic effects of these medications. To help prevent this mishap, counsel patients on keeping inhalation capsules with the inhaler, and instruct them on how to use the inhalers. As an added precaution, place an additional warning label on the inhalation capsules indicating that it is for inhalation use only. MedGuides The FDA has required the distribution of patient medication guides called MedGuides for many prescribed medications and prescribed over-the-counter medications for outpatient use. The FDA requires a MedGuide for medications if one or more of the following apply: Patient labeling could help prevent serious adverse effects. The drug product has serious risk(s) (relative to benefits) of which patients should be made aware because information concerning the risk(s) could affect patients decision to use, or to continue to use, the product. The drug product is important to the patient s health, and patient adherence to directions is crucial to the drug s effectiveness. Prior to distribution, the FDA must approve all MedGuides. These MedGuides must be provided to patients with each fill and refill. A prescriber can request to not distribute the MedGuide, but a request from the patient can overrule the prescriber s request. There are over 40 medication MedGuides currently available. For a complete list of MedGuides and to print these MedGuides go to: medication_guides.htm. 4
5 Zocor, Zoloft, and Proscar (continued from page 3) alternatives to sertraline include citalopram, fluoxetine, paroxetine, and Lexapro (escitalopram). Finasteride (generic for brand Proscar ) was made available in June Finasteride is a popular medication used in the treatment of Benign Prostatic Hyperplasia (BPH). Finasteride is a type II 5α-reductase inhibitor that prevents the conversion of testosterone into dihydrotestosterone (DHT). Teva will market the generic with 180-days of exclusivity. Dr. Reddy s Laboratories will also market a generic version of Proscar under a licensing agreement with brand patent holder Merck & Co. Finasteride is available on the Keystone Mercy Health Plan formulary with documented prior use of doxazosin, terazosin, or Flomax (tamsulosin). Avodart (dutasteride), also a 5α-reductase inhibitor, is another formulary option for treating BPH. References 1. Drug facts and comparisons. Alphagan P, Asmanex, Avodart, and Diovan HCT. Found at Accessed September Asmanex prescribing information. Schering Corporation. July Avodart prescribing information. GlaxoSmithKline. May Alphagan P 0.1% prescribing information. Allergan. August American Lung Association. Epidemiology and Statistics Unit Research and Program Services. Trends in Morbidity and Mortality. May NOP World. The Treatment of Asthma Study XXII. August US Food and Drug Administration Web site. Available at Accessed September 8, Symbicort package insert. Accessed September 8, GlaxoSmithKline. Package Insert for Advair Diskus. March GlaxoSmithKline. Package Insert for Servent Diskus. March O Hollaren, Mark T. Long-Acting Beta2-Agonists- Where Do We Stand? Medscape Pulmonary Medicine. 2006; 10(1). Retrieved August 16, 2006 from Advair Diskus, Advair HFA, Foradil, and Servent Diskus Information (Long Acting Beta Agonists). Retrieved August 16, 2006 from inforpage/laba/default.htm. 13. Schering Corporation. Package Insert for Foradil Aerolizer. June GlaxoSmithKline. Package Insert for Advair HFA. June O Mara, Neeta Bahal. The Safety of Long-Acting Beta-2 Agonists in Patients with Asthma. Pharmacist s Letter/Prescriber s Letter 2005; 21(9): Accidental Oral Administration of Capsules for Inhalation Devices. FDA Patient Safety News. Show#43, September Retrieved August 21, 2006 from cdfdocs/psn/printer/cfm?id= Woelfel, Joseph. Oral Administration of Capsules for Inhalation. Pharmacist s Letter/Prescriber s Letter 2005; 21(6): Drug Products with Medication Guides. Pharmacist s Letter/Prescriber s Letter 2006; 22(3): Medication Guides. Retrieved August 16, 2006 from medication_guides.htm. 20. Schering Corporation. Package Insert for Asmanex Twisthaler. July Asmanex (Mometason Furoate Inhalation Powder). Pharmacist s Letter/Prescriber s Letter 2005; 21(9): FDA Approval Retrieved August 18, 2006 from Alliant Pharmaceuticals, Inc. Package Insert for Orapred ODT. May MediMedia USA, Inc. c2006. Available from: Medscape Medical News, c2005. Available from: 5
6 Script Notes We welcome your thoughts, comments and/or suggestions. Do you have an idea for a story? Is there information we can provide to help you? All correspondence concerning Script Notes should be sent to: Andrew Maiorini, PharmD Keystone Mercy Health Plan 200 Stevens Drive Philadelphia, PA andrew.maiorini@performrx.com Editor: The Quarterly Pharmacy and Therapeutics Newsletter for Keystone Mercy Health Plan Participating Providers Denise Cubbin, PharmD Associate Vice President, Clinical Programs Contributing Editors: Mark R. Lawson, PharmD, RPh Supervisor, DUR/MTM Andrew Maiorini, PharmD Senior Clinical Pharmacist, Formulary Michelle M. Mason, PharmD Senior Clinical Pharmacist, DUR/MTM Rosellen Rajan, PharmD, Clinical Pharmacist, Formulary Margaret Shepherd, RPh Clinical Projects Pharmacist and Interim Supervisor, Formulary Jocelyn Scout, PharmD Clinical Pharmacist, Formulary 200 Stevens Drive Philadelphia, PA 19113
Aerospan (flunisolide)
STRENGTH DOSAGE FORM ROUTE GPID 80mcg/actuation HFA aerosol inhaler w/ Inhaled 35718 8.9 g/canister adapter MANUFACTURER Meda Pharmaceuticals INDICATION Aerospan Inhalation Aerosol is indicated for the
More information12/18/2017. Disclosures. Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationInhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath.
Inhaled bronchodilators relax constricted airways and treat the noisy part of asthma: coughing, wheezing, choking and shortness of breath. AccuNeb inhalation 0.021% solution: 0.63mg/3mL 3-4 times solution
More informationAsthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing
Asthma Management Updates: A Focus on Long-acting Muscarinic Antagonists and Intermittent Inhaled Corticosteroid Dosing Diana M. Sobieraj, PharmD, BCPS Assistant Professor University of Connecticut School
More informationDrug Class Monograph
Drug Class Monograph Class: Inhaled Corticosteroids Drugs: Aerospan (flunisolide), Advair Diskus, Advair HFA (fluticasone/salmeterol), Alvesco (ciclesonide), Arnuity Ellipta (fluticasone furoate), Asmanex
More informationTRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder
TRELEGY ELLIPTA (fluticasone-umeclidinium-vilanterol) aerosol powder Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 16 Years and Older The Canadian Thoracic Society and other international asthma
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fasenra) Reference Number: CP.PHAR.## Effective Date: 01.16.18 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Fluticasone/Salmeterol (Advair Diskus, Advair HFA) Reference Number: CP.PMN.31 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan See Important Reminder
More informationDOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL
DOD PHARMACY AND THERAPEUTICS COMMITTEE RECOMMENDATIONS INFORMATION FOR THE UNIFORM FORMULARY BENEFICIARY ADVISORY PANEL I. Uniform Formulary Review Process Under 10 U.S.C. 1074g, as implemented by 32
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP 3 Main Categories Inhaled Respiratory Drugs Binds to beta-2 receptors Relaxation of smooth muscles in the lung
More informationKey features and changes to these four components of asthma care include:
Guidelines for the Diagnosis and Management of Asthma in Adults Clinical Practice Guideline MedStar Health These guidelines are provided to assist physicians and other clinicians in making decisions regarding
More informationSelect Inhaled Respiratory Agents
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationInhaled Corticosteroids Drug Class Prior Authorization Protocol
Inhaled Corticosteroids Drug Class Prior Authorization Protocol Line of Business: Medi-Cal P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed through review
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP October 23, 2017 Learning Objectives Be able to list at least 3 major adverse effects of inhaled medications
More informationA Visual Approach to Simplifying Respiratory Drug Regimens
Adverse Effects of Inhaled Medications A Visual Approach to Simplifying Respiratory Drug Regimens Stephanie Cheng, PharmD, MPH, BCGP June 28, 2017 Drug Category Beta 2 agonists antagonists Adverse Effects
More informationQUANTITY LIMIT CRITERIA. BROVANA (arformoterol tartrate) SEREVENT DISKUS (salmeterol) STRIVERDI RESPIMAT (olodaterol)
Carelirst. +.V Family of health care plans DRUG CLASS COMBINATIONS QUANTITY LIMIT CRITERIA LONG ACTING BETA2-ADRENERGIC AGONIST, ORAL INHALATION BRAND NAME (generic) LONG-ACTING BETA2-ADRENERGIC AGONISTS:
More informationSummary of Lothian Joint Formulary Amendments
Summary of Lothian Joint Formulary Amendments The purpose of this summary is to detail the main changes to the LJF sections and provide additional information on the reasons for some of the changes. The
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More information1.* Dosage. A. Adults
Aerosolized Agents (Metered-Dose Inhalers) - Inhaled Anti-Inflammatory Drugs: Corticosteroids [Developed, January 1995; Revised, February, 1997; August 1997; March 1998; February 1999; January 2000; March
More informationAIRDUO RESPICLICK (fluticasone-salmeterol) aerosol DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol
DULERA (mometasone furoate and formoterol fumarate dihydrate) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationFirst to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida
First to Market or 505 (b)2 CMC Considerations IPAC-RS/UF Orlando Inhalation Conference Orlando, Florida Prasad Peri, Ph.D., Branch Chief, ONDQA, FDA March 19, 2014 1 Topics for discussion Introduction
More informationAdjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older
Adjustment of Inhaled Controller Therapy of Asthma in the Yellow Zone, Based on the Inhaler Product Used in the Green Zone Age 12 Years and Older The Canadian Thacic Society recommends a tempary, greater
More informationClinical Policy: Omalizumab (Xolair) Reference Number: ERX.SPA.141 Effective Date: Last Review Date: 08.17
Clinical Policy: (Xolair) Reference Number: ERX.SPA.141 Effective Date: 03.01.14 Last Review Date: 08.17 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationAllergies and Asthma 5/21/2013. Objectives. Allergic Rhinitis (AR): Risk Factor for ASTHMA. Rhinitis and Asthma
Allergies and Asthma Presented By: Dr. Fadwa Gillanders, Pharm.D Clinical Pharmacy Specialist May 2013 Objectives Understand the relationship between asthma and allergic rhinitis Understand what is going
More informationMedications Affecting The Respiratory System
Medications Affecting The Respiratory System Overview Asthma is a chronic inflammatory disorder of the airways. It is an intermittent and reversible airflow obstruction that affects the bronchioles. The
More informationCommon Inhaled Asthma Medications Dose Comparison and Tips for Use
Detail-Document #210303 This Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER March 2005 ~ Volume 21 ~ Number 210303 Common Inhaled Asthma Medications
More informationOrally Inhaled Corticosteroids to 2022
Greystone Research Associates 1+603-595-4340 April 2015 Orally Inhaled Corticosteroids to 2022 Drugs, Devices, Markets and Forecasts Contents A Comprehensive Market Analysis Report Scope & Overview 2 Table
More informationreslizumab (Cinqair )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationDiagnosis and Management of Asthma
Supporting Evidence: Diagnosis and Management of Asthma The subdivision of this section is: Appendix B Tables Copyright 2016 by 1 Eleventh Edition/December 2016 Appendix B Asthma Summary Tables Class:
More informationReference ID:
1 MEDICATION GUIDE 2 ADVAIR [ad vair] DISKUS 100/50 3 (fluticasone propionate 100 mcg and salmeterol 50 mcg inhalation powder) 4 ADVAIR DISKUS 250/50 5 (fluticasone propionate 250 mcg and salmeterol 50
More informationA COPD medication delivery device option: an overview of the NEOHALER
A COPD medication delivery device option: an overview of the NEOHALER 2017 Sunovion Pharmaceuticals Inc. All rights reserved 9/17 RESP019-17 Indication and Boxed Warning INDICATION ARCAPTA NEOHALER (indacaterol)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationClinical Policy: Mepolizumab (Nucala) Reference Number: ERX.SPA.214 Effective Date:
Clinical Policy: (Nucala) Reference Number: ERX.SPA.214 Effective Date: 07.01.16 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationCHARM ASTHMA TREATMENT GUIDELINE
NHS City and Hackney Prescribing Guidelines Adults ( 12 years of age) CHARM ASTHMA TREATMENT GUIDELINE Written by: Hetal Dhruve (Specialist Respiratory Pharmacist, City and Hackney CCG) Checked by: Prof
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46 Effective Date: Last Review Date: 08.18
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11.01.11 Last Review Date: 08.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationSafe, effective, affordable drug choices: online tool for payers and patients.
Executive summary: Rising healthcare costs and greater access to medical information drive patients to seek options for their drug therapy. The MedAlternatives database by Gold Standard/Elsevier empowers
More informationbenralizumab (Fasenra )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationMedications for Managing COPD in Hospice Patients. Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources
Medications for Managing COPD in Hospice Patients Jim Joyner, PharmD, CGP Director of Clinical Operations Outcome Resources Goal of medications in COPD Decrease symptoms and/or complications Reduce frequency
More informationMEDICATION GUIDE. ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol
MEDICATION GUIDE ADVAIR [ad vair] HFA 45/21 (fluticasone propionate 45 mcg and salmeterol 21 mcg) Inhalation Aerosol ADVAIR HFA 115/21 (fluticasone propionate 115 mcg and salmeterol 21 mcg) Inhalation
More informationFoundations of Pharmacology
Pharmacologic Management of Asthma Objectives: 1. Review the physiological basis for asthma therapy 2. Discuss the differences between SABA and LABA 3. Discuss the role of inhaled and oral systemic corticosteroids
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Seebri Neohaler) Reference Number: CP.CPA.150 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy
More informationBreath of Fresh Air. nniversary 20th. New National Asthma Survey: How Does Your Asthma Compare? Long-Acting Bronchodilators: Why All the Fuss?
Information, news and advice for improving asthma well-being Volume 12, No. 1 Summer 2010 New National Asthma Survey: How Does Your Asthma Compare? nniversary 20th Sometimes if one has to live with a chronic
More informationNHS Dumfries & Galloway Triple therapy in COPD patients over 16 years
Title of Project: NHS Dumfries & Galloway Triple therapy in COPD patients over 16 years 1 Reason for the review Respiratory prescribing is long term and can be costly. Appropriate choice and use of inhaled
More informationSupplementary materials
Supplementary materials Table S1 Patient comorbidities by diagnosis Total Asthma n (%) 5348 (148.4) COPD n (%) 4563 (143.4) ACOS n (%) 469 (197.9) No other comorbidities 95 (26.4) 614 (19.3) 27 (11.4)
More informationCombination Beta2-Agonist/Corticosteroid Inhalers Policy Number: Last Review: Origination: Next Review: Policy When Policy Topic is covered:
Combina ation Beta2-Agonist/Corticosteroid Inhalers Policy Number: 5.01.572 Origination: 06/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for the combination beta2-agonist/corticosteroid
More informationThe clinical effectiveness and costeffectiveness. treatment of chronic asthma in children under the age of 12 years
The clinical effectiveness and costeffectiveness of corticosteroids for the treatment of chronic asthma in children under the age of 12 years Submission of evidence from AstraZeneca UK Ltd regarding the
More informationAsthma By Mayo Clinic staff
MayoClinic.com reprints This single copy is for your personal, noncommercial use only. For permission to reprint multiple copies or to order presentation-ready copies for distribution, use the reprints
More informationTHE COPD PRESCRIBING TOOL
THE COPD PRESCRIBING TOOL Revised edition, 2017 www.bpac.org.nz/copd CLASSIFICATION The COPD prescribing tool This tool provides pharmacological treatment options for patients with COPD based on their
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationUniform Formulary Decisions 9 January 2014
Beneficiary Advisory Panel Handout Uniform Formulary Decisions 9 January 2014 Purpose: The purpose of this handout is to provide the BAP members with a reference document for the clinical effective presentation
More informationDose. Route. Units. Given. Dose. Route. Units. Given
Chapter 4 Respiratory Andrew Stanton SALBUTAMOL (in acute asthma) 5 in acute asthma Nebulised (driven by oxygen not air) 4 6 hourly In acute severe asthma not responding to initial treatment or in life-threatening
More informationANTINEOPLASTIC DRUGS CHAPTER 21. Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component
ANTINEOPLASTIC DRUGS CHAPTER 21 Antineoplastic drugs - designed to treat malignancies, now also used to treat diseases with inflammatory component Tx of malignancies Antineoplastic drugs: methotrexate
More informationPolicy Evaluation: Step Therapy Prior Authorization of Combination Inhaled Corticosteroid / Long-Acting Beta-Agonists
Drug Use Research & Management Program OHA Division of Medical Assistance Programs 500 Summer Street NE, E35; Salem, OR 97301-1079 Phone 503-947-5220 Fax 503-947-1119 Policy Evaluation: Step Therapy Prior
More informationLong-acting bronchodilators: their properties and place in treatment
Long-acting bronchodilators: their properties and place in treatment Steve Chaplin MSc, MRPharmS and Paul Walker BMedSci (Hons), MD, FRCP Steve Chaplin and Dr Paul KEY POINTS Walker provide an overview
More informationCOPD Update: Focus on Intensifying LABA, LAMA and ICS Therapy
Update: Focus on Intensifying LABA, LAMA and ICS Therapy B.C. Provincial Academic Detailing Service February 2017 Background In Canada, approximately 20 inhaled medications are approved to treat Chronic
More informationWomen Beware-The Threat of COPD
Page 1 Speaker: Catherine Cooke attained her Bachelor in Pharmacy from the University of Iowa and then went on to receive her Pharm.D. from the Medical University of South Carolina. Subsequently, she completed
More information10/18/2012. Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C
Penn State University Children s Hospital JODIE STABINSKI CRNP MSN AE-C Daily: Long-Term Control Corticosteroids (inhaled and systemic) Long-acting beta 2 -agonists (Serevent, Foradil) Methylxanthines
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.PMN.69 Effective Date: 11/15 Last Review Date: 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important regulatory
More informationFerris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS
Ferris State University College of Pharmacy MPA CE Symposium 2016 Paul Thill, PharmD, BCPS Objectives Categorize the new asthma and COPD inhalers in to existing or newly created categories Discuss the
More informationPharmacy Costs: Can I Make a Difference?
Pharmacy Costs: Can I Make a Difference? Pharmaceutical Market Dynamics What is driving Rx cost up? No New Blockbusters Patent Expirations OTC Market Dynamics Availability Pharmaceutical Companies Unfortunately,
More informationCLINICAL MEDICAL POLICY
CLINICAL MEDICAL POLICY Policy Name: Xolair (omalizumab) Policy Number: MP-051-MD-DE Responsible Department(s): Medical Management; Clinical Pharmacy Provider Notice Date: 10/01/2017 Original Effective
More informationAlberta Childhood Asthma Pathway for Primary Care
Asthma Diagnosis Box 1 Diagnosis: Based on symptom pattern, careful and thorough history of symptoms (wheeze, cough, night waking and activity limitations), and assessment of family history of asthma and
More informationInterventions to improve adherence to inhaled steroids for asthma. Respiratory department
Interventions to improve adherence to inhaled steroids for asthma Respiratory department Content Overview Research References Overview Asthma is a chronic breathing condition that affects more than 300
More informationWhy Asthma Still Kills The National Review of Asthma Deaths (NRAD)
APPROVED FINAL VERSION NHS Protect Why Asthma Still Kills The National Review of Asthma Deaths (NRAD) Summary of Recommendations for GP Practices and Community Pharmacies Author: Anne Henry Contact: anne.henry@nhs.net
More informationProposal on subsidy changes for some respiratory inhalation products and access restrictions to combination inhalers.
30 August 2011 Proposal on changes for some respiratory products and access restrictions to combination inhalers. As notified on 16 June 2011, PHARMAC has been considering options for managing the funding
More informationDrug Guide. April New Specialty Drug Approvals. New Formulations for Existing Drugs
April 2013 The MedTrak Drug Guide provides a monthly update on recent approvals by the Food and Drug Administration (FDA). Use the chart below as a valuable reference tool. Additional detailed information
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationPharmacist Objectives. Pulmonary Update. Outline. Technician Objectives. GOLD Guidelines. COPD Diagnosis 9/22/2017
Pharmacist Objectives Pulmonary Update Patty Marshik, PharmD Associate Professor University of New Mexico College of Pharmacy pmarshik@salud.unm.edu Discuss the new Global Initiative for Chronic Obstructive
More informationCinqair (reslizumab injection for intravenous use)
Cinqair (reslizumab injection for intravenous use) Policy Number: 5.02.522 Last Review: 04/2018 Origination: 04/2016 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationBrooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C
Brooke L. Gildon, Pharm.D., BCPS, BCPPS, AE C Associate Professor of Pharmacy Practice Southwestern Oklahoma State University College of Pharmacy Oklahoma Society of Health System Pharmacists Annual Meeting
More informationNucala (mepolizumab injection for subcutaneous use)
Nucala (mepolizumab injection for subcutaneous use) Policy Number: 5.01.612 Last Review: 01/2018 Origination: 02/2016 Next Review: 02/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will
More informationCHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES
CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) TREATMENT GUIDELINES Document Description Document Type Service Application Version Guidelines All healthcare professionals(hcps) caring for patients with asthma
More informationOnline supplementary material
Online supplementary material Add-on long-acting β2-agonist (LABA) in a separate inhaler as asthma step-up therapy versus increased dose of inhaled corticosteroid (ICS) or ICS/LABA combination inhaler
More informationClinical Policy: Dupilumab (Dupixent) Reference Number: ERX.SPA.49 Effective Date:
Clinical Policy: (Dupixent) Reference Number: ERX.SPA.49 Effective Date: 06.01.17 Last Review Date: 02.19 Revision Log See Important Reminder at the end of this policy for important regulatory and legal
More informationBetter Living with Obstructive Pulmonary Disease A Patient Guide
Better Living with Obstructive Pulmonary Disease A Patient Guide Second Edition November 2012 Queensland Health a Better Living with Chronic Obstructive Pulmonary Disease A Patient Guide is a joint project
More informationBudesonide equivalent dosing
Budesonide equivalent dosing dosage, adverse reactions, pharmacology and more. Budesonide 0.5mg Nebuliser Suspension (Breath Ltd) - Summary of Product Characteristics (SmPC) by Actavis UK Ltd 11-9-2012
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nucala) Reference Number: CP.PHAR.200 Effective Date: 04.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder at
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationARBS MEDICATION(S) SUBJECT TO STEP THERAPY DIOVAN HCT MG TAB, DIOVAN HCT MG TABLET
ARBS DIOVAN HCT 160-12.5 MG TAB, DIOVAN HCT 80-12.5 MG TABLET 30-day trial of a Step 1 drug in the previous 120 days is required. Step 1 Drugs: Losartan, Losartan/HCTZ PAGE 1 LAST UPDATED 05/2016 BILE
More informationAPPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe
APPENDIX 1 Printable point-of-care tables Asthma Action Plan Yellow Zone Formulation Table Region: Europe Instructions: Print on 8.5 x14 (216 x 279 mm) paper (Legal size) Medication in Green Zone Change
More informationTHEOPHYLLINE WITH INHALED CORTICOSTEROIDS (TWICS) TRIAL SELF MANAGMENT / ACTION PLANS GENUAIR INHALERS: POTENTIAL SAFETY ISSUE
I S S U E 4 M A R C H / A R P I L 2 0 1 6 Endorsed December 2014 I N S I D E T H I S I S S U E : Theophylline with Inhaled Corticosteroids (TWICS) Trial Genuair Inhaler: Potential Safety Issue 1 Self Management
More informationNot available 100/6mcg 2 BD formoterol (Fostair MDI) 100/6mcg 33
COMMISSIONING POLICY RECOMMENDATION TREATMENT ADVISORY GROUP FLUTICASONE FUROATE/VILANTEROL COMBINATION INHALER - ASTHMA Policy agreed by Vale of York CCG (date) Drug, Treatment, Device name Fluticasone
More informationDisclosure. Case. Objectives. Case Continued. Inhalers. Asthma: A GINA Update to the NAEPP 2007 Guidelines 1/20/2015
Disclosure Asthma: A GINA Update to the NAEPP 2007 Guidelines Robert (RC) Hellinga, Pharm.D. PGY 1 Pharmacy Resident Wolfson Children s Hospital/Baptist Health I do not have a vested interest in or affiliation
More informationCOPD Medications Coverage Summary Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes
COPD Medications Coverage Summary Drug Non-Insured Health Benefits Coverage SABA Bricanyl turbuhaler Yes Yes Ventolin MDI + generics Yes Yes Ventolin Diskus NO NO Yukon Pharmacare/Chronic Disease Program
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 1Q18 January February
BRAND NAME Xhance GENERIC NAME Fluticasone propionate MANUFACTURER Optinose DATE OF APPROVAL September 18 th, 2017 PRODUCT LAUNCH DATE 1 Second quarter of 2018 REVIEW TYPE Review type 1 (RT1): New Drug
More informationOmalizumab (Xolair ) ( Genentech, Inc., Novartis Pharmaceuticals Corp.) September Indication
( Genentech, Inc., Novartis Pharmaceuticals Corp.) September 2003 Indication The FDA recently approved Omalizumab on June 20, 2003 for adults and adolescents (12 years of age and above) with moderate to
More informationRespiratory Inhalers. Identification Guide Version 3
Respiratory Inhalers Identification Guide Version 3 This booklet has been prepared by NHSGGC Medicines Information. Endorsed by NHSGGC Respiratory Managed Clinical Network, February 2017. Designed by Medical
More informationSTRIVERDI RESPIMAT (olodaterol hcl) aerosol
STRIVERDI RESPIMAT (olodaterol hcl) aerosol Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationStudent Paper PHARMACY PRACTICE. Keywords: asthma, inhalers, patient education
Assessment of Asthma Inhaler Technique in Two Community Pharmacies Nicole Farabaugh, PharmD Candidate; Ashlee McMillan, PharmD, BCACP; and Gretchen Garofoli, PharmD, BCACP WVU School of Pharmacy Keywords:
More informationBNF CHAPTER 3: RESPIRATORY
3.1 BRONCHODILATORS BNF CHAPTER 3: RESPIRATORY 3.1.1.1 SELECTIVE BETA 2 -AGONISTS Short acting Salbutamol 100 micrograms/actuation aerosol inhaler 100 micrograms/actuation breath-actuated (e.g., Easi-Breathe
More informationSummary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol)
EMA/639304/2014 Summary of the risk management plan (RMP) for Budesonide/Formoterol Teva (budesonide / formoterol) This is a summary of the risk management plan (RMP) for Budesonide/Formoterol Teva, which
More informationWomen Beware The Threat of COPD
Page 1 Women Beware The Threat of COPD Catherine E. Cooke, PharmD, BCPS, PAHM President, PosiHealth, Inc. & Clinical Associate Professor, University of Maryland School of Pharmacy Supported by an education
More informationPosition within the Organisation
ASTHMA TREATMENT GUIDELINES Document Description Document Type Service Application Guidelines All healthcare professionals(hcps) caring for patients with asthma Version 4.0 Ratification date September
More informationDrug Monograph. Brand Name: Arcapta Neohaler. Generic Name: Indacaterol. Manufacturer¹,²: Novartis
Drug Monograph Brand Name: Arcapta Neohaler Generic Name: Indacaterol Manufacturer¹,²: Novartis Drug Class¹,²,³, : Beta2-Adrenergic Agonist, Long-Acting Uses: Labeled Uses¹,²,³, : Used for long-term maintenance
More informationEffective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017
Protocol Title: Adult Asthma Protocol Effective Date: 4/27/2016 Version: 1.0 Approval By: CCC Clinical Delivery Steering Planned Review Date: 4/27/2017 1 Purpose & Objective This protocol provides evidence-based
More informationAmitriptyline Hydrochloride Heart Health & BP Amlodipine Besylate 5mg Norvasc Antibiotics Amoxicillin 500 mg Amoxil
School Corp Formulary Antiviral Acyclovir 400mg Zovirax Asthma Advair Diskus Diskus 250/50 Fluticasone/Salmeterol Asthma Albuterol Sulfate 2.5 mg/3 ml Proventil Arthritis and Pain Allendronate Sodium 70
More information